Molecular structure of Daunorubicin hydrochloride, CAS Number: 23541-50-6
Daunorubicin hydrochloride (CAS 23541-50-6)
See product citations (4)
Application:
Daunorubicin hydrochloride is a DNA intercalator which may suppress acute leukemia proliferation
CAS Number:
23541-50-6
Purity:
≥90%
Molecular Weight:
563.98
Molecular Formula:
C27H29NO10•HCl
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Daunorubicin hydrochloride is a compound extensively studied in biochemical and molecular biology research due to its ability to intercalate with DNA. This intercalation disrupts the function of nucleic acids and is used by researchers to study the effects of such disruptions on DNA replication and RNA synthesis. In molecular biology experiments, daunorubicin hydrochloride is used as a tool to understand the dynamics of DNA-protein interactions and the mechanisms of DNA damage and repair. Its fluorescence properties also make it useful in various assays where it can serve as a probe for the visualization of cellular components. Additionally, the compound is employed in biophysical studies to investigate the structural changes in DNA and chromatin upon binding of intercalative agents, providing insights into the conformational aspects of nucleic acid structures. The hydrochloride salt form of daunorubicin ensures high solubility in water-based solutions, making it suitable for a range of experimental conditions.
Daunorubicin hydrochloride (CAS 23541-50-6) References
- Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). | Woodman, RJ., et al. 1975. Cancer Chemother Rep. 59: 689-95. PMID: 1175163
- Sturcture-activity relationship of daunorubicin and its peptide derivatives. | Wilson, DW., et al. 1976. J Med Chem. 19: 381-4. PMID: 1255661
- The anthracyclines: will we ever find a better doxorubicin? | Weiss, RB. 1992. Semin Oncol. 19: 670-86. PMID: 1462166
- Daunomycin intercalation stabilizes distinct backbone conformations of DNA. | Trieb, M., et al. 2004. J Biomol Struct Dyn. 21: 713-24. PMID: 14769064
- The effect of doxorubicin, daunorubicin and 4'-epidoxorubicin on the exogenous c-myc promoter in mouse erythroleukemia cells. | Eliopoulos, A., et al. 1991. Anticancer Res. 11: 2153-7. PMID: 1776855
- Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. | Sauter, KA., et al. 2011. Cancer Biol Ther. 11: 1008-16. PMID: 21464611
- The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers. | Shao, M., et al. 2012. J Liposome Res. 22: 168-76. PMID: 22428938
- Cell viabilities and biodegradation rates of DNA/protamine complexes with two different molecular weights of DNA. | Mori, N., et al. 2013. J Biomed Mater Res B Appl Biomater. 101: 743-51. PMID: 23359567
- Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. | Herfindal, L., et al. 2013. BMC Cancer. 13: 341. PMID: 23841896
- Sustained delivery of a HIF-1 antagonist for ocular neovascularization. | Iwase, T., et al. 2013. J Control Release. 172: 625-33. PMID: 24126220
- Role of the calmodulin inhibitor trifluoperazine on the induction and expression of cell cycle traverse perturbations and cytotoxicity of daunorubicin and doxorubicin (adriamycin) in doxorubicin-resistant P388 mouse leukaemia cells. | Ganapathi, R., et al. 1986. Br J Cancer. 53: 561-6. PMID: 3707847
- A new series of reductive amination derivatives of daunorubicin: syntheses, partition coefficients, and DNA binding. | Yen, SF., et al. 1984. J Pharm Sci. 73: 1575-9. PMID: 6394744
- Selective mitochondrial alterations induced by a single dose of daunorubicin or 4-demethoxydaunorubicin in mouse ventricular myocardium. | Zanon, PL., et al. 1980. Tumori. 66: 27-34. PMID: 6929617
- Effect of daunorubicin and adriamycin on nucleic acid synthesis of serum stimulated mouse embryo fibroblasts. | Supino, R., et al. 1977. Tumori. 63: 31-42. PMID: 878021
- Alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. | Taatjes, DJ., et al. 1996. J Med Chem. 39: 4135-8. PMID: 8863788
Inhibitor of:
AI481877, ALDH3B2, ANKRD13D, BC049762, C6orf167, Carbonyl reductase 1, DDX10, DDX19B, DNA pol β, FIGNL2, Gm22, GTF3A, Histone cluster 2 H3C, Histone cluster 2 H4B, HMG-2, HMGN3, HoxC9, HYAL2, I-SceI, LDH-AL6A, LHX4, LOC255130, MA1, Mitochondrial Topo I, Myeloid Marker, OBFC2B, OFCC1, p91, POP5, PUS1, REPIN1, RRP36, RWDD2A, RYBP, scc-112_Pds5a, SPR, SSBP2, SULT1B1, Topo I, Topo II, YTHDF1, and ZNF154.Activator of:
1700055N04Rik, Esp1, LASS, LRWD1, NAP1L4, NOP16, RBM10, RREB1, and TDRD3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Daunorubicin hydrochloride, 10 mg | sc-200921 | 10 mg | $103.00 | |||
Daunorubicin hydrochloride, 50 mg | sc-200921A | 50 mg | $429.00 | |||
Daunorubicin hydrochloride, 250 mg | sc-200921B | 250 mg | $821.00 | |||
Daunorubicin hydrochloride, 1 g | sc-200921C | 1 g | $1538.00 |